{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:07:01Z","timestamp":1789150021259,"version":"build-2803163510"},"reference-count":49,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The increasing complexity of modern protein therapeutics and the demand for faster development of new therapeutics require not only advanced analytical tools that provide in-depth understanding of the product quality attributes (PQAs) that are crucial for safety and efficacy but also the implementation of a control strategy to ensure that the released drug product meets the desired quality profile. The multi-attribute method (MAM), a liquid chromatography\u2013mass spectrometry (LC-MS) approach, has emerged as a transformative solution that provides site-specific monitoring of multiple critical quality attributes (CQAs) in a single workflow, replacing several conventional profile-based assays. The MAM achieves comprehensive quality oversight through two primary mechanisms: targeted attribute quantitation (TAQ) for the simultaneous quantification of predefined known modifications, and new peak detection (NPD) for identifying unforeseen impurities, thereby establishing a robust, \u201cdouble-layered\u201d control strategy. This article reviews the practical challenges and current industry practices for successfully implementing the MAM within current good manufacturing practice (cGMP) environments. The successful transition of the MAM from a specialized characterization tool to a validated quality control (QC) cornerstone relies on a framework built upon four foundational pillars: stringent instrument qualification paired with compliance-ready informatics, proactive and strictly scheduled instrument maintenance, rigorous system suitability testing (SST), and phase-appropriate method validation and transfer. The challenges of global method transfer and the solutions to mitigate inter-laboratory variability are discussed. Finally, the review explores the emerging trends shaping the future of the MAM in QC and the critical role of the MAM in facilitating real-time release testing (RTRT) in next-generation autonomous manufacturing.<\/jats:p>","DOI":"10.3390\/ph19091444","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:14:59Z","timestamp":1789146899000},"page":"1444","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protein Therapeutic Quality Control Using Multi-Attribute Method (MAM): Challenges and Current Practice in cGMP Environments"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4240-8568","authenticated-orcid":false,"given":"Zhiqi","family":"Hao","sequence":"first","affiliation":[{"name":"Pharma Technical Development, Genentech, A Member of the Roche Group, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Yu","sequence":"additional","affiliation":[{"name":"Pharma Technical Development, Genentech, A Member of the Roche Group, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-4578","authenticated-orcid":false,"given":"Anja","family":"Bathke","sequence":"additional","affiliation":[{"name":"Pharma Technical Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Yim","sequence":"additional","affiliation":[{"name":"Pharma Technical Development, Genentech, A Member of the Roche Group, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Buettner","sequence":"additional","affiliation":[{"name":"Pharma Technical Development Analytics, Roche Diagnostics GmbH, 82377 Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-5573","authenticated-orcid":false,"given":"Feng","family":"Yang","sequence":"additional","affiliation":[{"name":"Pharma Technical Development, Genentech, A Member of the Roche Group, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Reusch","sequence":"additional","affiliation":[{"name":"Pharma Technical Development Analytics, Roche Diagnostics GmbH, 82377 Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Pharma Technical Development, Genentech, A Member of the Roche Group, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ejps.2012.06.009","article-title":"Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT)","volume":"47","author":"Aksu","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1021\/acs.analchem.8b04596","article-title":"Using the Analytical Target Profile to Drive the Analytical Method Lifecycle","volume":"91","author":"Jackson","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"868727","DOI":"10.1155\/2015\/868727","article-title":"Analytical quality by design: A tool for regulatory flexibility and robust analytics","volume":"2015","author":"Peraman","year":"2015","journal-title":"Int. J. Anal. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","article-title":"Understanding pharmaceutical quality by design","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.chroma.2013.11.057","article-title":"Modern chromatographic and mass spectrometric techniques for protein biopharmaceutical characterization","volume":"1335","author":"Sandra","year":"2014","journal-title":"J. Chromatogr. A"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1021\/acs.analchem.5b04561","article-title":"Chromatographic, Electrophoretic, and Mass Spectrometric Methods for the Analytical Characterization of Protein Biopharmaceuticals","volume":"88","author":"Fekete","year":"2016","journal-title":"Anal. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/ac3032355","article-title":"Characterization of Therapeutic Antibodies and Related Products","volume":"85","author":"Beck","year":"2013","journal-title":"Anal. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.biotechadv.2011.05.006","article-title":"Advances and challenges in analytical characterization of biotechnology products: Mass spectrometry-based approaches to study properties and behavior of protein therapeutics","volume":"30","author":"Kaltashov","year":"2012","journal-title":"Biotechnol. Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s13361-016-1531-9","article-title":"A Retrospective Evaluation of the Use of Mass Spectrometry in FDA Biologics License Applications","volume":"28","author":"Rogstad","year":"2017","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1021\/ac901193n","article-title":"Large-Scale Identification and Quantification of Covalent Modifications in Therapeutic Proteins","volume":"81","author":"Zhang","year":"2009","journal-title":"Anal. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1208\/s12248-017-0168-3","article-title":"A View on the Importance of \u201cMulti-Attribute Method\u201d for Measuring Purity of Biopharmaceuticals and Improving Overall Control Strategy","volume":"20","author":"Rogers","year":"2017","journal-title":"AAPS J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/19420862.2015.1069454","article-title":"Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics","volume":"7","author":"Rogers","year":"2015","journal-title":"mAbs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2197668","DOI":"10.1080\/19420862.2023.2197668","article-title":"Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control","volume":"15","author":"Yang","year":"2023","journal-title":"mAbs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4155\/bio-2017-0004","article-title":"Characterization and QC of biopharmaceuticals by MS-based \u2018multi-attribute method\u2019: Advantages and challenges","volume":"9","author":"Zhang","year":"2017","journal-title":"Bioanalysis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.tibtech.2020.06.007","article-title":"Advancing Mass Spectrometry Technology in cGMP Environments","volume":"38","author":"Ren","year":"2020","journal-title":"Trends Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41596-022-00785-5","article-title":"Comprehensive multi-attribute method workflow for biotherapeutic characterization and current good manufacturing practices testing","volume":"18","author":"Jakes","year":"2023","journal-title":"Nat. Protoc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14170","DOI":"10.1021\/acs.analchem.9b03808","article-title":"Multi-Attribute Method for Quality Control of Therapeutic Proteins","volume":"91","author":"Rogstad","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1002\/cpz1.927","article-title":"Multi-Attribute Method (MAM) Analytical Workflow for Biotherapeutic Protein Characterization from Process Development to QC","volume":"3","author":"Jakes","year":"2023","journal-title":"Curr. Protoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e9222","DOI":"10.1002\/rcm.9222","article-title":"Automated multi-attribute method sample preparation using high-throughput buffer exchange tips","volume":"36","author":"Ogata","year":"2022","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2572411","DOI":"10.1080\/19420862.2025.2572411","article-title":"Development, qualification, and application of a highly efficient and robust new peak detection workflow for the LC-MS peptide mapping multi-attribute method","volume":"17","author":"Pohl","year":"2025","journal-title":"mAbs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1021\/jasms.2c00355","article-title":"A Robust Purity Method for Biotherapeutics Using New Peak Detection in an LC-MS-Based Multi-Attribute Method","volume":"34","author":"Sadek","year":"2023","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"114330","DOI":"10.1016\/j.jpba.2021.114330","article-title":"Multi-attribute method performance profile for quality control of monoclonal antibody therapeutics","volume":"205","author":"Hao","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Shipman, J., Oyugi, M., Marzan, T.A., Geerlof-Vidavsky, I., Kirkpatrick, D., Zhu, H., Rasangika, M., and Rogstad, S. (2025). A Multi-Laboratory, Multi-Platform Analysis of the Multi-Attribute Method. Pharmaceuticals, 18.","DOI":"10.3390\/ph18111613"},{"key":"ref_24","unstructured":"USP (2023). General Chapter <1060> Multi-Attribute Method for Therapeutic Proteins, USP."},{"key":"ref_25","unstructured":"USP (2024). General Chapter <1058> Analytical Instrument Qualification, USP."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1080\/10408347.2023.2238058","article-title":"Multi-Attribute Method (MAM): An Emerging Analytical Workflow for Biopharmaceutical Characterization, Batch Release and cGMP Purity Testing at the Peptide and Intact Protein Level","volume":"54","author":"Jakes","year":"2024","journal-title":"Crit. Rev. Anal. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1021\/jasms.0c00415","article-title":"New Peak Detection Performance Metrics from the MAM Consortium Interlaboratory Study","volume":"32","author":"Mouchahoir","year":"2021","journal-title":"J. Am. Soc. Mass. Spectrom."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00216-018-0848-6","article-title":"Development of an LC-MS\/MS peptide mapping protocol for the NISTmAb","volume":"410","author":"Mouchahoir","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejpb.2023.04.024","article-title":"Technical considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory","volume":"188","author":"Pohl","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1021\/jasms.2c00129","article-title":"Attribute Analytics Performance Metrics from the MAM Consortium Interlaboratory Study","volume":"33","author":"Mouchahoir","year":"2022","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_31","unstructured":"ICH (2024). Q2(R2) Validation of Analytical Procedures, Guidance for Industry, ICH."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1074\/mcp.C119.001652","article-title":"Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies","volume":"19","author":"Ghosh","year":"2020","journal-title":"Mol. Cell. Proteom."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1021\/acs.analchem.9b05036","article-title":"Implementation of a High-Resolution Liquid Chromatography\u2013Mass Spectrometry Method in Quality Control Laboratories for Release and Stability Testing of a Commercial Antibody Product","volume":"92","author":"Sokolowska","year":"2020","journal-title":"Anal. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1080\/19420862.2017.1364326","article-title":"A Quadrupole Dalton-based multi-attribute method for product characterization, process development, and quality control of therapeutic proteins","volume":"9","author":"Xu","year":"2017","journal-title":"mAbs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2174\/1389201024666221111160403","article-title":"Interlaboratory Co-validation of a UPLC-ToF MS MAM Method for Truncations of a Fc Fusion Protein","volume":"24","author":"Wang","year":"2023","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"115564","DOI":"10.1016\/j.jpba.2023.115564","article-title":"Method validation and new peak detection for the liquid chromatography-mass spectrometry multi-attribute method","volume":"234","author":"Oyugi","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.xphs.2022.10.018","article-title":"Analytical Performance Evaluation of Identity, Quality-Attribute Monitoring and new Peak Detection in a Platform Multi-Attribute Method Using Lys-C Digestion for Characterization and Quality Control of Therapeutic Monoclonal Antibodies","volume":"112","author":"Li","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"122540","DOI":"10.1016\/j.jchromb.2021.122540","article-title":"Automated mass spectrometry multi-attribute method analyses for process development and characterization of mAbs","volume":"1166","author":"Song","year":"2021","journal-title":"J. Chromatogr. B"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"113988","DOI":"10.1016\/j.jpba.2021.113988","article-title":"Fully automated peptide mapping multi-attribute method by liquid chromatography\u2013mass spectrometry with robotic liquid handling system","volume":"198","author":"Qian","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1978131","DOI":"10.1080\/19420862.2021.1978131","article-title":"Enhancing the multi-attribute method through an automated and high-throughput sample preparation","volume":"13","author":"Sitasuwan","year":"2021","journal-title":"mAbs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1021\/jasms.0c00432","article-title":"Tracking the Behavior of Monoclonal Antibody Product Quality Attributes Using a Multi-Attribute Method Workflow","volume":"32","author":"Jakes","year":"2021","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Carvalho, S.B., Gomes, R.A., Pfenninger, A., Fischer, M., Strotbek, M., Isidro, I.A., Tug\u00e7u, N., and Gomes-Alves, P. (2022). Multi attribute method implementation using a High Resolution Mass Spectrometry platform: From sample preparation to batch analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0262711"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1021\/acs.analchem.1c01029","article-title":"ID-MAM: A Validated Identity and Multi-Attribute Monitoring Method for Commercial Release and Stability Testing of a Bispecific Antibody","volume":"93","author":"Evans","year":"2021","journal-title":"Anal. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1783062","DOI":"10.1080\/19420862.2020.1783062","article-title":"An evaluation of instrument types for mass spectrometry-based multi-attribute analysis of biotherapeutics","volume":"12","author":"Zhang","year":"2020","journal-title":"mAbs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpb.2022.07.005","article-title":"Intact multi-attribute method (iMAM): A flexible tool for the analysis of monoclonal antibodies","volume":"177","author":"Carillo","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/19420862.2017.1279773","article-title":"Subunit mass analysis for monitoring antibody oxidation","volume":"9","author":"Sokolowska","year":"2017","journal-title":"mAbs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"466711","DOI":"10.1016\/j.chroma.2026.466711","article-title":"Multi-attribute methods in antibody-drug conjugate characterization and quality control: Opportunities, challenges, and regulatory outlook","volume":"1768","author":"Kumar","year":"2026","journal-title":"J. Chromatogr. A"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"41198","DOI":"10.1038\/s41598-025-24922-8","article-title":"Multi-attribute monitoring (MAM) methodology for glycosylated subunit vaccines","volume":"15","author":"Shajahan","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_49","first-page":"100409","article-title":"Transformative roles of digital twins from drug discovery to continuous manufacturing: Pharmaceutical and biopharmaceutical perspectives","volume":"10","author":"Maharjan","year":"2025","journal-title":"Int. J. Pharm. X"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1444\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:18:46Z","timestamp":1789147126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ph19091444"],"URL":"https:\/\/doi.org\/10.3390\/ph19091444","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}